Scripps Clinic Torrey Pines

The trials here

What the 7 trials at this site are about, from their registry records.

Conditions

• Lung cancer2 trials
• Colorectal cancer1 trial
• Multiple myeloma1 trial
• Pancreatic cancer1 trial
• Parkinson disease1 trial
• Ulcerative colitis1 trial

Phase

• Phase 12 trials
• Phase 1/21 trial
• Phase 21 trial
• Phase 31 trial

Status

• Recruiting3 trials
• Terminated2 trials
• Active, not recruiting1 trial
• Not yet recruiting1 trial

Lead sponsor

• Darren Sigal, MD1 trial
• Navire Pharma Inc., a BridgeBio company1 trial
• OBI Pharma, Inc1 trial
• Pfizer1 trial
• Regeneron Pharmaceuticals1 trial
• and 2 more

Running trials

• Recruiting

  BAL/BOT/agenT-797 in pMMR CRC With Liver Metastases

  NCT07550088· Phase 2· Darren Sigal, MD· Source

  Contact: Darren Sigal Principal Investigator, MD

• Recruiting

  A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection

  NCT07128199· Phase 3· Taiho Oncology, Inc.· Source

  Contact: Taiho Oncology, Inc.

• Recruiting

  An Observational Study of Etrasimod in Adult Patients With Moderate to Severe Ulcerative Colitis

  NCT06398626· Pfizer· Source

• Recruiting

  A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

  NCT05137054· Phase 1· Regeneron Pharmaceuticals· Source

  Contact: Clinical Trials Administrator

• Active, not recruiting

  The Parkinson's Disease NeuroGenebank at Scripps Clinic Registry

  NCT00766948· Scripps Translational Science Institute· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Colorectal cancer1 recruiting
• Lung cancer1 recruiting
• Multiple myeloma1 recruiting
• Ulcerative colitis1 recruiting

Closed trials

• Terminated

  SHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS Mutation

  NCT05375084· Phase 1· Navire Pharma Inc., a BridgeBio company· Source

• Terminated

  A Phase I/II Study of OBI-3424 in Subjects with Advanced Solid Tumors

  NCT03592264· Phase 1/2· OBI Pharma, Inc· Source